BML Capital Management, LLC holds a concentrated book of 15 stocks worth $175.1M as of Q2 2026 (disclosed Aug 7, 2026, a ~38-day 13F lag). This quarter they opened Engene Therapeutics Inc and trimmed Aclaris Therapeutics Inc. Their largest long position is Aclaris Therapeutics Inc at 36% of the equity book. They also disclosed $954K in put options (a bearish bet), shown separately below and excluded from the equity book. Cloning the disclosed picks since 2024 would be +214% (+64.6%/yr). That is a simulation of the disclosed long book, not audited returns.
Following at the filing date actually beat the quarter-end book by 70.0 points over this window.
Growth of $10,000 cloning BML Capital Management, LLC's disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~38 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
93% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as BML Capital Management, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 15 / 15 | $2.1B |
| MORGAN STANLEY | 15 / 15 | $1.5B |
| UBS Group AG | 15 / 15 | $641.1M |
| ROYAL BANK OF CANADA | 15 / 15 | $522.9M |
| BlackRock, Inc. | 14 / 15 | $7.2B |
| JPMORGAN CHASE & CO | 14 / 15 | $455.3M |
| Ken Griffin | 14 / 15 | $392.6M |
| BARCLAYS PLC | 14 / 15 | $356.6M |
Ranked by how many of BML Capital Management, LLC's top 15 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Aclaris Therapeutics Inc COM | $63.3M | 11.97M | 36.2% | ▼−16% Reduced · −2.3M sh | |
| 2 | Atea Pharmaceuticals Inc COM | $32.3M | 6.95M | 18.5% | ▼−1.5% Reduced · −106K sh | |
| 3 | Engene Therapeutics Inc COM *A* | $11.5M | 6.67M | 6.6% | ▲New New position | |
| 4 | Kraft Heinz Co COM | $11.0M | 465.0K | 6.3% | ▲+272% Added · +340K sh | |
| 5 | Outset Med Inc COM NEW | $10.9M | 2.52M | 6.2% | ▲+32% Added · +618K sh | |
| 6 | Carmax Inc COM | $9.1M | 172.5K | 5.2% | ▲+11% Added · +18K sh | |
| 7 | Tillys Inc CL A | $9.0M | 2.15M | 5.2% | —Held | |
| 8 | PMV Pharmaceuticals Inc COM | $7.1M | 5.33M | 4.1% | ▲+0.2% Added · +10K sh | |
| 9 | Instil Bio Inc COM NEW | $5.0M | 645.6K | 2.8% | —Held | |
| 10 | Target Corp COM | $4.9M | 37.5K | 2.8% | —Held | |
| 11 | Oramed Pharmaceuticals Inc COM NEW | $4.2M | 866.3K | 2.4% | ▼−73% Reduced · −2.3M sh | |
| 12 | Janux Therapeutics Inc COM | $2.4M | 155.0K | 1.4% | —Held | |
| 13 | Pliant Therapeutics Inc COM | $1.8M | 1.55M | 1.0% | —Held | |
| 14 | Connect Biopharma Hldgs Ltd SHS | $1.4M | 573.3K | 0.8% | ▲+40% Added · +164K sh | |
| 15 | Imagenebio Inc COM | $1.2M | 200.7K | 0.7% | —Held |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1616824/holdings"
Use Arkolith to show BML Capital Management, LLC's latest holdings, largest changes, and filing provenance.
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| PUT · bearish | WALMART INCWMT | $386K | 335 |
| PUT · bearish | CORE SCIENTIFIC INCCORZ | $298K | 800 |
| PUT · bearish | TESLA INCTSLA | $270K | 375 |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | Aug 7, 2026 | 18 | $176.1M | 13F-HR |
| Q1 2026 | Mar 31, 2026 | May 6, 2026 | 16 | $155.8M | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 3, 2026 | 16 | $115.7M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 10, 2025 | 20 | $109.2M | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 11, 2025 | 24 | $132.2M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 7, 2025 | 27 | $123.6M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 7, 2025 | 25 | $161.0M | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 5, 2024 | 29 | $169.9M | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 7, 2024 | 28 | $140.1M | 13F-HR |
| Q1 2024 | Mar 31, 2024 | Apr 24, 2024 | 32 | $151.7M | 13F-HR/A |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.